Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.0%

6 terminated/withdrawn out of 149 trials

Success Rate

93.8%

+7.2% vs industry average

Late-Stage Pipeline

14%

21 trials in Phase 3/4

Results Transparency

4 of 90 completed trials have results

Key Signals

19 recruiting4 with results

Enrollment Performance

Analytics

N/A

45(48.9%)

Phase 2

20(21.7%)

Phase 4

11(12.0%)

Phase 3

10(10.9%)

Phase 1

6(6.5%)

92Total

N/A(45)

Phase 2(20)

Phase 4(11)

Phase 3(10)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (149)

Showing 20 of 149 trials

NCT07488910Phase 4Not Yet Recruiting

Dynamic Networks in Depression Treatment: Mechanisms of Change in Pharmacological, Psychological and Combined Treatment of Depression

Role: lead

NCT06530888Not ApplicableActive Not Recruiting

Feasibility of Process-based Therapy in a Naturalistic Setting

Role: lead

NCT03763617Not ApplicableCompleted

Periosteal Inhibition Technique for Ridge Preservation A Prospective Study

Role: collaborator

NCT07422844Recruiting

Dynamic Network Response to TMS Treatment

Role: lead

NCT07064590Not ApplicableRecruiting

Effects of Frontopolar TMS in Alcohol Craving

Role: lead

NCT06648889Phase 2Recruiting

Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Role: lead

NCT07161310Not ApplicableRecruiting

Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors

Role: lead

NCT02881086Phase 3Completed

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Role: lead

NCT02872987Recruiting

GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

Role: lead

NCT03188796Phase 3Recruiting

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Role: collaborator

NCT03480438Phase 2Completed

Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab

Role: lead

NCT03075423Phase 2Completed

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

Role: lead

NCT07008261Recruiting

Robot-assisted Cystectomies With Regard to Blood Loss, Pain and Transfusions.

Role: lead

NCT03978260Completed

Preoperative Anaemia prevaLence In surgiCal patiEnts

Role: collaborator

NCT05182385Phase 1Active Not Recruiting

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Role: lead

NCT05284227Not ApplicableCompleted

Artificial Intelligence-augmented Perioperative Clinical Decision Support

Role: collaborator

NCT06988345Active Not Recruiting

Juxtarenal Aortic Aneurysm

Role: collaborator

NCT06201936Recruiting

EPIDURAL- Evaluation of Preexisting Information Regarding Neuroaxial Procedures for Labour Analgesia

Role: lead

NCT05623670Completed

Prospective Evaluation of Jugular Vein Thrombi After CPB Cervical Cannulation